^
Association details:
| Biomarker: | HER-2 amplification |
|---|---|
| Cancer: | Endometrial Adenocarcinoma |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + lapatinib (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Dual HER2 Targeting Impedes Growth of HER2 Gene Amplified Uterine Serous Carcinoma Xenografts
Excerpt:
Lapatinib decreased in vitro proliferation of all cell lines and in vivo growth of HER2 amplified xenografts (ARK2, EnCa1). In addition, dual therapy with trastuzumab and lapatinib resulted in significant anti-tumor activity only in ARK2 and EnCa1 tumors.
DOI:
10.1158/1078-0432.CCR-14-1647
